PRMT5 and central nervous system cancer: Evaluation of CNV of PMRGs in glioma tumors identified significant depletion in MTAP. Protein arginine methyltransferase 5 (PRMT5) is inhibited by high levels of MTA, rendering PRMT5-deficient cells more susceptible to PRMT5 inhibitors (48).